ABSTRACT
Objective To compare the transurenthral resection to radical cystectomy on muscle invasive bladder cancer, and to explore the factors affecting the prognosis. Methods Data of 74 patients with muscle invasive bladder can?cer were retrospectively analyzed. There were 38 cases underwent radical cystectomy (group A), and were treated with intra?venous chemotherapy after operation. There were 36 cases underwent transurenthral resection (group B), and were treated with intravenous and urinary bladder irrigation chemotherapy. All patients were followed up 61 (5-91) months. Data were compared between two groups including duration of surgery, intraoperative blood loss, the cumulative length of hospital stay, cancer recurrence rate and 5-year survival rate . The factors may affecting the prognosis in patients were collected and ana?lyzed by the Log-rank univariate and Cox multivariate analyzed. Results The values of operation time, intraoperative blood loss and the cumulative length of hospital stay were significantly lower in group B than those of group A ( P0.05). Results of the Log-rank univariate analysis showed that the tumor size≥5 cm and T3 stage were the important factors of 5-year relapse-free survival rate and 5-year overall survival rate. Results of the Cox multivariate analysis showed that the tumor size≥5 cm (RR=3.687, 95%CI:1.913-7.105, P<0.001) was the important factor of recurrence in patients after operation. T3 stage (RR=3.325, 95%CI:1.437-7.695, P=0.005) and tumor size≥5 cm (RR=5.017, 95%CI:2.440-10.317, P=0.002) were the risk fac?tors of the 5-year overall survival rate. Conclusion The transurenthral resection with intravenous and urinary bladder irri?gation chemotherapy deserves recommendation for the treatment of muscle invasive bladder cancer. Tumor size ≥5 cm and T3 stage are the important factors for the prognosis.
ABSTRACT
Objective To investigate clinical effects of transurethral resection of bladder tumor (TURBT) combined with postoperative perfusion of mitomycin C to urinary bladder on superficial bladder cancer. Methods 32 patients with superficial bladder cancer were treated by TURBT and discontinuous perfusion of mitomycin C (20mg/20ml) to urinary bladder. Results 32 cases of the superficial bladder cancers all were once ablated. 8 cases relapsed in 6 months to 2 years of postoperation, which were treated by TURBT and discontinuous perfusion of mitomycin C to urinary bladder again, and relapse was not found from postoperation to present. Conclusions Treatment of TURBT combined with perfusion of mitomycin C on superficial bladder cancer is repeatable, simple, safe and effective.